Akero Therapeutics, Inc. Common Stock
Symbol: AKRO (NASDAQ)
47.66
▲ (3.10%) 1.435
Company Description:
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
Key Stats
- Today's Open: $46.35
- Today's High: $47.848
- Today's Low: $46.11
- Today's Volume: 745.04K
- Yesterday Close: $46.22
- Yesterday High: $47.32
- Yesterday Low: $46.155
- Yesterday Volume: 711.15K
- Last Min Volume: 0
- Last Min High: $47.701
- Last Min Low: $47.655
- Last Min VWAP: $0
Company Profile
- Name: Akero Therapeutics, Inc. Common Stock
- Website: https://www.akerotx.com
- Listed Date: 2019-06-20
- Location: SOUTH SAN FRANCISCO, CA
- Market Status: Active
- CIK Number: 0001744659
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $3.82B
- Round Lot: 100
- Outstanding Shares: 79.99M
- Asset Type: CS
RECENT FILINGS FOR AKRO
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-12 | 4 | View |
| 2025-09-12 | 4 | View |
| 2025-09-12 | 4 | View |
| 2025-09-12 | 4 | View |
| 2025-09-12 | 4 | View |
| 2025-09-10 | 4 | View |
| 2025-09-10 | 144 | View |
| 2025-09-04 | 4 | View |
| 2025-08-19 | 4 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-13 | 4 | View |
| 2025-08-13 | 4 | View |
| 2025-08-12 | 4 | View |
| 2025-08-12 | 144 | View |
| 2025-08-12 | 144 | View |
| 2025-08-12 | SCHEDULE 13G/A | View |
| 2025-08-08 | 8-K | View |
| 2025-08-08 | 10-Q | View |
| 2025-08-07 | 4 | View |
Latest News on AKRO